2024 年，非小细胞肺癌（NSCLC）治疗领域迎来了累累硕果。尤其是针对 EGFR 突变 III 期不可切除 NSCLC 的靶向巩固治疗研究，取得了令人振奋的突破性 ...

Even within these fields, researchers would often define themselves as integrin researchers, cadherin experts or epidermal growth factor receptor (EGFR) signalling specialists. Over the last 20 ...

Several targets almost fulfill this requisite: tenascin-C, podoplanin/aggrus, EGF receptor (EGFR), EGFRvIII ... extradomain B of fibronectin, integrin α v β 3, histone H1 complexed to ...

Integrins are very attractive therapeutic targets in oncology. The anti-tumor mechanisms of integrin-targeting drugs have been validated both in vitroand in vivo. Integrin-targeting drugs are ...